<DOC>
	<DOCNO>NCT00700882</DOCNO>
	<brief_summary>RATIONALE : Dasatinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well dasatinib work treat patient locally advance metastatic mucosal melanoma acral melanoma .</brief_summary>
	<brief_title>Dasatinib Treating Patients With Locally Advanced Metastatic Mucosal Melanoma , Acral Melanoma , Vulvovaginal Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate objective tumor response rate patient KIT-positive , unresectable , locally advanced metastatic acral mucosal melanoma treat dasatinib monotherapy . Secondary - To estimate response duration patient treat drug . - To estimate progression-free survival patient treated drug . - To evaluate safety profile drug patient . - To evaluate PDGFR expression activation Src family kinases tumor sample correlate parameter response treatment . OUTLINE : This multicenter study . Patients receive oral dasatinib twice daily day 1-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Tissue sample may collect patient correlative study . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm melanoma 1 follow subtypes : Acral melanoma ( define occur palm , sol , subungual site ) Melanoma arise vagina and/or vulva Melanoma arise mucosal surface ( vagina vulva ) Unresectable locally advance metastatic disease cKIT mutation identify polymerase chain reaction ( PCR ) sequence meet 1 follow criterion : At least 1 mutation exon 9 , 11 , 13 , 17 , 18 At least 1 mutation exon list Metastatic tumor block require evaluation KIT mutation amplification Measurable disease , define least one measurable lesion RECIST criterion Prior radiotherapy measurable lesion allow provided radiographic evidence progression lesion No ocular melanoma Baseline bone scan require patient know bone metastasis , elevate alkaline phosphatase , symptom raise suspicion bone metastases History clinical evidence brain metastasis allow provide follow criterion meet : Completed radiotherapy surgical treatment brain lesion AND evidence CNS progression ≥ 8 week Must require corticosteroid treatment cerebral edema brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 WBC ≥ 3,000/mm³ Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 2.0 time upper limit normal ( ULN ) OR creatinine clearance ≥ 40 mL/min Total bilirubin ≤ 1.5 time ULN ( &lt; 3.0 time ULN presence Gilbert disease ) AST ALT ≤ 2.5 time ULN ( ≤ 5.0 time ULN presence liver metastasis ) Serum potassium magnesium normal ( repletion allow ) Total serum calcium ionized calcium normal INR ≤ 1.5 PTT normal Therapeutic anticoagulation warfarin allow provide INR ≤ 1.5 PTT normal prior initiate anticoagulation therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence bleed diathesis No malignancy except basal cell squamous cell skin cancer , carcinoma situ cervix , ductal lobular carcinoma situ breast , malignancy patient continuously diseasefree ≥ 5 year Patients must clinically significant cardiovascular disease include follow : Myocardial infarction ventricular tachyarrhythmia within 6 month Prolonged QTc &gt; 480 msec ( Fridericia correction ) Ejection fraction less institutional normal Major conduction abnormality ( unless cardiac pacemaker present ) Patients cardiopulmonary symptom unknown cause ( e.g. , shortness breath , chest pain , etc . ) evaluate baseline echocardiogram without stress test need addition electrocardiogram ( EKG ) rule QTc prolongation Patients underlying cardiopulmonary dysfunction exclude study No uncontrolled hypertension , define systolic blood pressure ≥ 150 mm Hg diastolic blood pressure ≥ 90 mm Hg Hypertension adequately control medication allow No QTc prolongation , define QTc interval ≥ 450 msec No concurrent serious illness include , limited , ongoing active infection require parenteral antibiotic No psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior treatment target therapy direct CKIT/PDGFR ( e.g. , imatinib mesylate sunitinib malate ) Prior limb perfusion allow Prior systemic therapy allow At least 4 week since prior chemotherapy immunotherapy Prior adjuvant neoadjuvant chemotherapy immunotherapy allow At least 4 week since prior radiotherapy No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( i.e. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>acral lentiginous malignant melanoma</keyword>
	<keyword>mucosal melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
</DOC>